| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -29,474 | -18,663 |
| Depreciation | 500 | 337 |
| Non-cash lease expense | 407 | 210 |
| Change in fair value of sepa, warrant and revenue base redemption liabilities | -4,097 | -1,312 |
| Change in fair value of contingent earnout liability | -2,404 | 120 |
| Paid-in-kind interest | 800 | - |
| Stock-based compensation expense | 6,934 | 3,512 |
| Allowance for credit losses | 130 | 96 |
| Loss on disposal of property and equipment | -117 | -117 |
| Amortization of debt issuance costs | 767 | 492 |
| Accounts receivable | 43 | 540 |
| Inventory, net | -772 | -241 |
| Prepaid expenses and other assets | -648 | -777 |
| Deposits | 0 | 0 |
| Non-cash interest expense | - | 584 |
| Operating lease liabilities | -107 | -81 |
| Change in fair value of orbimed warrants and revenue base redemption liabilities | - | 147 |
| Trade payables and accrued liabilities | 1,328 | -186 |
| Net cash used in operating activities | -15,528 | -11,819 |
| Purchases of property and equipment | 877 | 661 |
| Proceeds from the disposal of property and equipment | 80 | 40 |
| Net cash used in investing activities | -797 | -621 |
| Proceeds from the issuance of common stock | 22,211 | 22,211 |
| Common stock issuance costs | 1,549 | 1,549 |
| Debt issuance costs | 520 | 520 |
| Proceeds from the issuance of debt | 10,000 | 10,000 |
| Payments on finance lease liabilities | 78 | 72 |
| Proceeds from the exercise of stock options for common stock | 423 | 335 |
| Net cash provided by financing activities | 30,487 | 30,405 |
| Increase (decrease) in cash, cash equivalents and restricted cash | 14,162 | 17,965 |
| Cash and cash equivalents at beginning of period | 8,875 | - |
| Cash and cash equivalents at end of period | 23,037 | - |
TriSalus Life Sciences, Inc. (TLSIW)
TriSalus Life Sciences, Inc. (TLSIW)